Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer
{{output}}
Background: CTT1403 (177Lu-CTT2001), an irreversible phosphoramidate PSMA inhibitor developed by Cancer Targeted Technology, was initially synthesized using a two-step radiolabeling method and has previously been evaluated in fir... ...
